SCHEMBL18289975

SCHEMBL18289975

Nc1nccc2c1[nH]c(=O)n2[C@@H]1CCCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA5 O75582 1/20 0.43
▸ HTR2B P41595 2/20 0.39
▸ HTR3E A5X5Y0 1/20 0.39
▸ HTR3B O95264 1/20 0.39
▸ HTR3A P46098 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ HTR3D Q70Z44 1/20 0.39
▸ HTR3C Q8WXA8 1/20 0.39
▸ HTR6 P50406 6/20 0.38
▸ ROCK1 Q13464 2/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ JAK2 O60674 3/20 0.34
▸ JAK1 P23458 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30866992 1.00 RPS6KA5 (0.43) RPS6KA5HTR2BHTR3EHTR3BHTR3A
SCHEMBL18818255 1.00 RPS6KA5 (0.43) RPS6KA5HTR2BHTR3EHTR3BHTR3A
SCHEMBL28908346 0.87 ADORA3 (0.45) ADORA3ADORA2BJAK2JAK1JAK3
SCHEMBL18285473 0.81 JAK2 (0.40) RPS6KA5HTR2BHTR3EHTR3BHTR3A
SCHEMBL29737109 0.80 RXFP1 (0.34) —
SCHEMBL29614483 0.79 TLR7 (0.41) RPS6KA5HTR2BHTR3EHTR3BHTR3A
SCHEMBL25616564 0.79 CHRM2 (0.46) KCNH2JAK2JAK1JAK3TLR7
SCHEMBL30111811 0.76 BTK (0.39) BTKJAK2JAK1JAK3TLR7
SCHEMBL18285554 0.76 BTK (0.45) BTKJAK2JAK1JAK3
SCHEMBL18285551 0.76 BTK (0.45) BTKJAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 — — CN disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 — — EP disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 — — EP disclosed
EP-3912979-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2021-11-24 — — EP disclosed
EP-3912979-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2021-11-24 — — EP disclosed
CN-113149983-A Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2021-07-23 — — CN disclosed
EP-3303334-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-06-02 — — EP disclosed
EP-3303334-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-06-02 — — EP disclosed
CN-106459049-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2020-11-27 — — CN disclosed
US-20180162861-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-06-14 — — US disclosed
US-20180162861-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-06-14 — — US disclosed
US-9688676-B2 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2017-06-27 — — US disclosed
US-9688676-B2 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2017-06-27 — — US disclosed
US-20170129890-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2017-05-11 — — US disclosed
US-20170129890-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2017-05-11 — — US disclosed
WO-2016196840-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162861-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK RPS6KA5 338/4885HTR2B 4654/4885HTR3E 4421/4885
US-20170129890-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK RPS6KA5 338/4885HTR2B 4654/4885HTR3E 4421/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK RPS6KA5 338/4885HTR2B 4654/4885HTR3E 4421/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK RPS6KA5 338/4885HTR2B 4654/4885HTR3E 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback